Clozapine and COVID-19: The authors respond.

J Psychiatry Neurosci

From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind); the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles); the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer); the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane); the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane); the Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll); the Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany (Correll); the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hasan); the Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK (Howes); the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes, MacCabe); the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes); the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly); the Bronx Westchester Medical Group, New York, USA (Laitman); the North Region & Department of Psychosis, Institute of Mental Health, Singapore (Lee); the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee); the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark (Nielsen); the Mental Health Service Noord-Holland-Noord, Alkmaar, The Netherlands (Schulte); the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor); the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux); the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler); the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA (Freudenreich); and the Harvard Medical School, Boston, Massachusetts, USA (Freudenreich).

Published: July 2020

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828928PMC
http://dx.doi.org/10.1503/jpn.2045302DOI Listing

Publication Analysis

Top Keywords

clozapine covid-19
4
covid-19 authors
4
authors respond
4
clozapine
1
authors
1
respond
1

Similar Publications

Importance: Amid escalating mental health challenges among young individuals, intensified by the COVID-19 pandemic, analyzing postpandemic trends is critical.

Objective: To examine mental health care utilization and prescription rates for children, adolescents, and young adults before and after the COVID-19 pandemic.

Design, Setting, And Participants: This population-based time trend study used an interrupted time series analysis to examine mental health care and prescription patterns among the French population 25 years and younger.

View Article and Find Full Text PDF

Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study.

PLoS Med

December 2024

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.

Background: Clozapine is widely regarded as a highly efficacious psychotropic drug that is largely underused worldwide. Recent disproportionality analyses and nationwide case-control studies suggested a potential association between clozapine use and hematological malignancy (HM). Nevertheless, the absolute rate difference is not well-established due to the absence of analytic cohort studies.

View Article and Find Full Text PDF

Multi-level barriers and facilitators to implementing evidence-based antipsychotics in the treatment of early-phase schizophrenia.

Front Health Serv

October 2024

Department of Psychiatry and Behavioral Sciences and Center for Dissemination and Implementation Science, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

Introduction: Long-acting injectable (LAI) antipsychotic medications and clozapine are effective yet underutilized medical therapies in early intervention services. The purpose of this study was to conduct a pre-implementation evaluation of contextual determinants of early intervention programs to implement innovations optimizing LAI antipsychotic and clozapine use within a shared decision-making model.

Methods: Semi-structured interviews explored barriers and facilitators to implementing LAI antipsychotics and clozapine in early intervention services.

View Article and Find Full Text PDF

Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study.

Lancet Psychiatry

October 2024

Copenhagen Research Center for Biological and Precision Psychiatry, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address:

Background: Infection risk and mortality are increased in schizophrenia spectrum disorders, which was corroborated during the COVID-19 pandemic. However, evidence is lacking regarding the additional impact of antipsychotic drugs, and the highly debated safety of clozapine treatment during large-scale infection outbreaks. Therefore, we aimed to investigate risk of COVID-19 and non-COVID respiratory infections during exposure to antipsychotics.

View Article and Find Full Text PDF

The impact of COVID-19 public health measures on the utilization of antipsychotics in schizophrenia in Manitoba - A population-based study.

Schizophr Res

October 2024

College of Pharmacy, University of Manitoba, Winnipeg, Canada; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. Electronic address:

Article Synopsis
  • The study investigated how COVID-19 public health measures impacted access to antipsychotic medications for individuals with schizophrenia in Manitoba, Canada.
  • During the initial months of the pandemic (April-June 2020), there was a notable decline in new prescriptions for antipsychotics, even though overall usage remained stable compared to previous years.
  • The findings highlight the need for further research on how changes in medication access during the pandemic may affect outcomes for people with schizophrenia, which could inform future public health strategies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!